

Rob S Beanlands

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1368889/publications.pdf>

Version: 2024-02-01

304
papers

14,640
citations

19657

61
h-index

23533

111
g-index

328
all docs

328
docs citations

328
times ranked

9018
citing authors

#	ARTICLE	IF	CITATIONS
1	Data-driven motion correction rescues interpretation of rubidium PET scan with extreme breathing artifacts. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 818-822.	2.1	1
2	Diagnosis of unrecognized aortic dissection by hybrid PET/CT rubidium-82 imaging. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 848-850.	2.1	0
3	Prognostic utility of longitudinal quantification of PET myocardial blood flow early post heart transplantation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 712-723.	2.1	12
4	Age, Not Sex, Modifies the Effect of Frailty on Long-term Outcomes After Cardiac Surgery. <i>Annals of Surgery</i> , 2022, 275, 800-806.	4.2	13
5	Static CT myocardial perfusion imaging: image quality, artifacts including distribution and diagnostic performance compared to 82Rb PET. <i>European Journal of Hybrid Imaging</i> , 2022, 6, 1.	1.5	1
6	Evaluation of Lung Glucose Uptake with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/CT in Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Left Heart Disease. <i>Annals of Nuclear Cardiology</i> , 2022, , .	0.2	0
7	Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2784-2795.	2.1	8
8	Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1083-1090.	1.2	9
9	Reproducible Quantification of Regional Sympathetic Denervation with [11C]meta-Hydroxyephedrine PET Imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2745-2757.	2.1	5
10	Comparison of myocardial blood flow and flow reserve with dobutamine and dipyridamole stress using rubidium-82 positron emission tomography. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 34-45.	2.1	7
11	Prognostic importance of coincidental coronary artery calcification on FDG-PET/CT oncology studies. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1479-1488.	1.5	3
12	Keiichiro Yoshinaga, MD, PhD, FACC, FASNC. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 377-380.	2.1	1
13	Derivation of Patient-Defined Adverse Cardiovascular and Noncardiovascular Events Through a Modified Delphi Process. <i>JAMA Network Open</i> , 2021, 4, e2032095.	5.9	13
14	PET and SPECT Evaluation of Viable Dysfunctional Myocardium. , 2021, , 399-418.		0
15	Practical Guide for Interpreting and Reporting Cardiac PET Measurements of Myocardial Blood Flow: An Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1599-1615.	5.0	13
16	Practical guide for interpreting and reporting cardiac PET measurements of myocardial blood flow: an Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 768-787.	2.1	28
17	Guidance and Best Practices for Reestablishment of Non-Emergent Care in Nuclear Cardiology Laboratories During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC, IAEA, and SNMMI. <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 13-18.	0.8	12
18	Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 450-457.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Observational Cross-Sectional Study of Inflammatory Markers After Transient Ischemic Attacks, Acute Coronary Syndromes, and Vascular Stroke Events. <i>CJC Open</i> , 2021, 3, 675-679.	1.5	0
20	COUNTERPOINT: Should Isolated Cardiac Sarcoidosis Be Considered a Significant Manifestation of Sarcoidosis? No. <i>Chest</i> , 2021, 160, 38-42.	0.8	11
21	Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review. <i>Journal of the American Heart Association</i> , 2021, 10, e021183.	3.7	35
22	[11C]meta-hydroxyephedrine PET evaluation in experimental pulmonary arterial hypertension: Effects of carvedilol of right ventricular sympathetic function. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 407-422.	2.1	1
23	Regional Distribution of Fluorine-18-Flubrobenguane and Carbon-11-Hydroxyephedrine for Cardiac PET Imaging of Sympathetic Innervation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1425-1436.	5.3	16
24	Nuclear Imaging of the Cardiac Sympathetic Nervous System. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1036-1054.	5.3	40
25	OUTSMART HF. <i>Circulation</i> , 2020, 141, 818-827.	1.6	19
26	Effect of proton pump inhibitors on Rubidium-82 gastric uptake using positron emission tomography myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1443-1451.	2.1	5
27	Exploring Occupational, Recreational, and Environmental Associations in Patients With Clinically Manifest Cardiac Sarcoidosis. <i>CJC Open</i> , 2020, 2, 585-591.	1.5	4
28	Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. <i>Journal of the American Heart Association</i> , 2020, 9, e017086.	3.7	7
29	Treatment with corticosteroids is associated with an increase in ventricular arrhythmia burden in patients with clinically manifest cardiac sarcoidosis: Insights from implantable cardioverter-defibrillator diagnostics. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2751-2758.	1.7	13
30	Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1855-1862.	2.1	28
31	Guidance and Best Practices for Nuclear Cardiology Laboratories During the COVID-19 Pandemic. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011761.	2.6	7
32	Sex-specific temporal trends in ambulatory heart failure incidence, mortality and hospitalisation in Ontario, Canada from 1994 to 2013: a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e044126.	1.9	3
33	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1022-1029.	2.1	56
34	A Clinical Tool to Identify Candidates for Stress-First Myocardial Perfusion Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2193-2202.	5.3	8
35	Comparison of coronary CT angiography versus functional imaging for CABG patients: A resource utilization analysis. <i>IJC Heart and Vasculature</i> , 2020, 27, 100494.	1.1	1
36	The Future of Cardiac Molecular Imaging. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 367-385.	4.6	19

#	ARTICLE	IF	CITATIONS
37	Appropriate Use Criteria for PET Myocardial Perfusion Imaging. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1221-1265.	5.0	36
38	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. <i>Journal of Nuclear Medicine</i> , 2020, , jnumed.120.246686.	5.0	14
39	FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET. <i>EJNMMI Research</i> , 2020, 10, 154.	2.5	11
40	The Role of 18F-FDG PET/CT in Cardiac Sarcoidosis. <i>International Journal of Cardiovascular Sciences</i> , 2020, , .	0.1	1
41	ASNC's global impact: Transforming nuclear cardiology and making the world smaller. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1497-1499.	2.1	2
42	Stress Myocardial Perfusion PET Provides Incremental Risk Prediction in Patients with and Patients without Diabetes. <i>Radiology: Cardiothoracic Imaging</i> , 2019, 1, e180018.	2.5	5
43	Nuclear Cardiology, the Future is Now!. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 2159-2160.	2.1	0
44	Letter by Birnie et al Regarding Article, "Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis: Implications for the Diagnosis of Isolated Cardiac Sarcoidosis". <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009614.	2.6	0
45	The Current Role of Viability Imaging to Guide Revascularization and Therapy Decisions in Patients With Heart Failure and Reduced Left Ventricular Function. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1015-1029.	1.7	17
46	Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. <i>International Journal of Cardiology</i> , 2019, 289, 138-143.	1.7	25
47	Competency-Based Medical Education. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2505-2513.	5.3	11
48	Clinical performance of Rb-82 myocardial perfusion PET and Tc-99m-based SPECT in patients with extreme obesity. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 275-283.	2.1	16
49	Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2019, 19, 109-131.	0.7	8
50	Optimizing Risk Stratification and Noninvasive Diagnosis of Ischemic Heart Disease in Women. <i>Canadian Journal of Cardiology</i> , 2018, 34, 400-412.	1.7	7
51	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 269-297.	2.1	151
52	Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events. <i>IJC Heart and Vasculature</i> , 2018, 18, 12-16.	1.1	17
53	Appropriate Use Criteria for Cardiac Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2018, 33, 132-137.	1.5	22
54	Prognostic value of vasodilator response using rubidium-82 positron emission tomography myocardial perfusion imaging in patients with coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 538-548.	6.4	6

#	ARTICLE	IF	CITATIONS
55	Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. <i>Journal of Nuclear Medicine</i> , 2018, 59, 273-293.	5.0	163
56	Myocardial perfusion imaging: Lessons learned and work to be done—update. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 39-52.	2.1	19
57	Disability—free survival after coronary artery bypass grafting in women and men with heart failure. <i>Open Heart</i> , 2018, 5, e000911.	2.3	25
58	Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1137-1144.	1.7	9
59	Coronary artery microvascular dysfunction: Role of sex and arterial load. <i>International Journal of Cardiology</i> , 2018, 270, 42-47.	1.7	18
60	[¹⁸ F]-NaF PET/CT Identifies Active Calcification in Carotid Plaque. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 486-488.	5.3	38
61	Clinical PET Flow Reserve Imaging. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 578-581.	5.3	4
62	Inter- and Intraobserver Agreement of ¹⁸ F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1324-1329.	5.0	32
63	Can Functional Testing for Ischemia and Viability Guide Revascularization?. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 354-364.	5.3	19
64	Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 579-587.	7.1	95
65	IN THE PRESENCE OF SIGNIFICANT EPICARDIAL CORONARY DISEASE, DIABETES MELLITUS IS FURTHER ASSOCIATED WITH REDUCED MYOCARDIAL FLOW RESERVE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1401.	2.8	2
66	Using coronary calcification to exclude an ischemic etiology for cardiomyopathy: A validation study and systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 518-522.	1.7	7
67	Joint SNMMI—ASNC expert consensus document on the role of ¹⁸ F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1741-1758.	2.1	132
68	Rubidium 82 Positron Emission Tomography in Cardiac Allograft Vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, S296-S297.	0.6	0
69	Joint SNMMI—ASNC Expert Consensus Document on the Role of ¹⁸ F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1341-1353.	5.0	187
70	Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow. <i>Journal of Nuclear Medicine</i> , 2017, 58, 103-109.	5.0	61
71	Role of ¹⁸ F-Fluorodeoxyglucose/Positron Emission Tomography Imaging to Demonstrate Resolution of Acute Myocarditis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 293.e3-293.e5.	1.7	4
72	Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1979-1989.	2.1	23

#	ARTICLE	IF	CITATIONS
73	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1073-1089.	1.2	74
74	Clinical Management of Cardiac Sarcoidosis. <i>Annals of Nuclear Cardiology</i> , 2017, 3, 131-136.	0.2	3
75	Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging. <i>PLoS ONE</i> , 2017, 12, e0177451.	2.5	8
76	ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1187-1226.	2.1	450
77	Patient motion effects on the quantification of regional myocardial blood flow with dynamic PET imaging. <i>Medical Physics</i> , 2016, 43, 1829-1840.	3.0	68
78	Women Image Wisely. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 385-387.	5.3	7
79	The role of nuclear cardiac imaging in risk stratification of sudden cardiac death. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1380-1398.	2.1	5
80	American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1227-1231.	2.1	33
81	Cardiac Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 411-421.	2.8	400
82	American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1654-1656.	5.0	60
83	Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [¹⁸ F]FPyKYNE-losartan. <i>EJNMMI Research</i> , 2016, 6, 55.	2.5	4
84	Allograft Vasculopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 80-91.	2.8	205
85	Characterization of [¹⁸ F]FPyKYNE-Losartan for Imaging AT ₁ Receptors. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1612-1617.	5.0	11
86	Clinical PET Myocardial Perfusion Imaging and Flow Quantification. <i>Cardiology Clinics</i> , 2016, 34, 69-85.	2.2	34
87	Radionuclide Tracers for Myocardial Perfusion Imaging and Blood Flow Quantification. <i>Cardiology Clinics</i> , 2016, 34, 37-46.	2.2	15
88	Respiratory motion resulting in a pseudo-ischemia pattern on stress PET-CT imaging. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 159-160.	2.1	6
89	Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1424-1431.	1.2	53
90	The Journey of International Fellows: Have you been to America?. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 1161-1162.	2.1	2

#	ARTICLE	IF	CITATIONS
91	Development of reporter gene imaging techniques for long-term assessment of human circulating angiogenic cells. <i>Biomedical Materials (Bristol)</i> , 2015, 10, 034104.	3.3	1
92	Single low-dose CT scan optimized for rest-stress PET attenuation correction and quantification of coronary artery calcium. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 419-428.	2.1	27
93	The CREATE Method for Expressing Continuous Outcome Data in Absolute Terms for Use in Patient Treatment Decision Aids. <i>Medical Decision Making</i> , 2015, 35, 959-966.	2.4	0
94	Obesity and the Challenges of Noninvasive Imaging for the Detection of Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2015, 31, 223-226.	1.7	17
95	PET imaging of a collagen matrix reveals its effective injection and targeted retention in a mouse model of myocardial infarction. <i>Biomaterials</i> , 2015, 49, 18-26.	11.4	20
96	Evaluation of [¹¹ C]methyl-losartan and [¹¹ C]methyl-EXP3174 for PET imaging of renal AT1receptor in rats. <i>Nuclear Medicine and Biology</i> , 2015, 42, 850-857.	0.6	7
97	Positron Emission Tomography Myocardial Perfusion Imaging for Diagnosis and Risk Stratification in Obese Patients. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.6	2
98	Cardiac Imaging of Infiltrative Cardiomyopathies. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.6	1
99	Cardiac Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 657-668.	2.1	30
100	The role of nuclear imaging in pulmonary hypertension. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 141-157.	2.1	21
101	Imaging of the Biomaterial Structure and Function. , 2015, , 275-293.		1
102	Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 364-374.	1.2	96
103	Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middle-aged Adults. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 875-881.	1.7	150
104	Detection and severity classification of extracardiac interference in ⁸² Rb PET myocardial perfusion imaging. <i>Medical Physics</i> , 2014, 41, 102501.	3.0	7
105	Effects of Short-Term Continuous Positive Airway Pressure on Myocardial Sympathetic Nerve Function and Energetics in Patients With Heart Failure and Obstructive Sleep Apnea. <i>Circulation</i> , 2014, 130, 892-901.	1.6	80
106	SPECT gated blood pool phase analysis of lateral wall motion for prediction of CRT response. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 559-569.	1.5	10
107	Prognostic Value of PET-Myocardial Perfusion Imaging in Obese Patients. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 278-287.	5.3	62
108	Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 233-244.	2.1	27

#	ARTICLE	IF	CITATIONS
109	Clinical Interpretation Standards and Quality Assurance for the Multicenter PET/CT Trial Rubidium-ARMI. <i>Journal of Nuclear Medicine</i> , 2014, 55, 58-64.	5.0	40
110	Prognostic Value of Rubidium-82 Positron Emission Tomography in Patients After Heart Transplant. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 930-937.	2.6	96
111	Prognostic value of Rb-82 positron emission tomography myocardial perfusion imaging in coronary artery bypass patients. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 787-792.	1.2	16
112	The Novel Endothelin Receptor Antagonist, Macitentan, Improved Right Ventricular Function and Normalized Glucose Uptake in a Sugen5416/hypoxia Rat Model of Severe Pulmonary Artery Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, S73-S74.	1.7	0
113	An Evaluation of Right Ventricular Metabolism in Right Heart Failure Associated with Pulmonary Arterial Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, S73.	1.7	0
114	Synthesis and evaluation of the novel 2-[18F]fluoro-3-propoxy-triazole-pyridine-substituted losartan for imaging AT1 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3931-3937.	3.0	15
115	Myocardial Viability: It is Still Alive. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 358-374.	4.6	25
116	Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 829-841.	2.1	10
117	The role of integrin α_2 in cell and matrix therapy that improves perfusion, viability and function of infarcted myocardium. <i>Biomaterials</i> , 2014, 35, 4749-4758.	11.4	34
118	Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model. <i>EJNMMI Research</i> , 2013, 3, 48.	2.5	11
119	Atherosclerosis Imaging and the Canadian Atherosclerosis Imaging Network. <i>Canadian Journal of Cardiology</i> , 2013, 29, 297-303.	1.7	25
120	ASNC Model Coverage Policy: Cardiac positron emission tomographic imaging. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 916-947.	2.1	12
121	Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 845-856.	2.1	16
122	Epicardial adipose tissue thickness as a predictor of impaired microvascular function in patients with non-obstructive coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 804-812.	2.1	36
123	Characterizing the normal range of myocardial blood flow with 82rubidium and 13N-ammonia PET imaging. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 578-591.	2.1	54
124	The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2013, 20, 297-306.	2.1	73
125	Different Characteristics of Disease Detection Between 18F-Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and Cardiac Magnetic Resonance (CMR) in Patients With Conduction Disease Due to Cardiac Sarcoidosis. <i>Canadian Journal of Cardiology</i> , 2013, 29, S273.	1.7	2
126	Elevated Fatty Acid and Glucose Uptake in Right Ventricle in a Sugen 5416/Hypoxia Rat Model of Severe Pulmonary Artery Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, S249.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review. Canadian Journal of Cardiology, 2013, 29, 1034-1041.	1.7	219
128	Influence of Sex on Risk Stratification With Stress Myocardial Perfusion Rb-82 Positron Emission Tomography. Journal of the American College of Cardiology, 2013, 62, 1866-1876.	2.8	80
129	Anatomic Versus Physiologic Assessment of Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 1639-1653.	2.8	495
130	Computed tomographic coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE HF Project 1-C). Trials, 2013, 14, 443.	1.6	7
131	Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial. Trials, 2013, 14, 218.	1.6	51
132	Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. Journal of Nuclear Cardiology, 2013, 20, 969-975.	2.1	42
133	Myocardial Viability: Whom, What, Why, Which, and How?. Canadian Journal of Cardiology, 2013, 29, 399-402.	1.7	16
134	[18F]FPYKYNE- Losartan AT1 Receptor Binding Is Reduced in Chronic Kidney Disease Rat Model With Pet Imaging. Canadian Journal of Cardiology, 2013, 29, S311-S312.	1.7	0
135	Implications of the Discrepancy in Ejection Fraction Reporting Between Echocardiography and Radionuclide Angiography in a "Real-World" Tertiary Care Heart Function Clinic. Canadian Journal of Cardiology, 2013, 29, S140.	1.7	0
136	Scar imaging using multislice computed tomography versus metabolic imaging by F-18 FDG positron emission tomography: A pilot study. International Journal of Cardiology, 2013, 168, 739-745.	1.7	14
137	Prognostic Value of Rubidium-82 Positron Emission Tomography for Evaluation of Patients Following Cardiac Transplantation. Canadian Journal of Cardiology, 2013, 29, S138.	1.7	0
138	Evidence for Actively Inflamed Bilateral Carotid Plaque in Patients With Advanced Atherosclerosis, Insight From [18F]-Fluorodeoxyglucose Imaging: A Sub-Study of the Canadian Atherosclerosis Imaging Network (CAIN). Canadian Journal of Cardiology, 2013, 29, S137.	1.7	0
139	Analysis of [11C]methyl-candesartan kinetics in the rat kidney for the assessment of angiotensin II type 1 receptor density in vivo with PET. Nuclear Medicine and Biology, 2013, 40, 252-261.	0.6	12
140	Prognostic Value of Stress Myocardial Perfusion Positron Emission Tomography. Journal of the American College of Cardiology, 2013, 61, 176-184.	2.8	204
141	Cardiovascular Imaging: New Directions in an Evolving Landscape. Canadian Journal of Cardiology, 2013, 29, 257-259.	1.7	4
142	Isolated Cardiac Sarcoidosis: Establishing the Diagnosis With Electroanatomic Mapping-Guided Endomyocardial Biopsy. Canadian Journal of Cardiology, 2013, 29, 1015.e1-1015.e3.	1.7	63
143	Identification of Inflamed Aortic Plaque in Conventional Fluorodeoxyglucose "Positron Emission Tomography Myocardial Viability Studies. Canadian Journal of Cardiology, 2013, 29, 1069-1075.	1.7	3
144	Test "retest repeatability of quantitative cardiac 11C-meta-hydroxyephedrine measurements in rats by small animal positron emission tomography. Nuclear Medicine and Biology, 2013, 40, 676-681.	0.6	28

#	ARTICLE	IF	CITATIONS
145	Integrin $\alpha_2\beta_1$ Is Required for Synergistic Effect of Cells and Matrix Therapy in Improving the Perfusion, Viability and Function of Infarcted Hearts. Canadian Journal of Cardiology, 2013, 29, S377.	1.7	0
146	Cardiac PET: Metabolic and Functional Imaging of the Myocardium. Seminars in Nuclear Medicine, 2013, 43, 434-448.	4.6	31
147	In Vivo and Ex Vivo Imaging Demonstrate Effective Injection and Retention of a Collagen Matrix in a Mouse Model of Myocardial Infarction. Canadian Journal of Cardiology, 2013, 29, S307-S308.	1.7	0
148	Cell-based vasculogenic studies in preclinical models of chronic myocardial ischaemia and hibernation. Expert Opinion on Biological Therapy, 2013, 13, 411-428.	3.1	9
149	Lessons From the Tc-99m Shortage. Circulation: Cardiovascular Imaging, 2013, 6, 683-691.	2.6	12
150	Multisoftware Reproducibility Study of Stress and Rest Myocardial Blood Flow Assessed with 3D Dynamic PET/CT and a 1-Tissue-Compartment Model of ^{82}Rb Kinetics. Journal of Nuclear Medicine, 2013, 54, 571-577.	5.0	110
151	Preclinical Evaluation of Biopolymer-Delivered Circulating Angiogenic Cells in a Swine Model of Hibernating Myocardium. Circulation: Cardiovascular Imaging, 2013, 6, 982-991.	2.6	10
152	Is There an Association Between Clinical Presentation and the Location and Extent of Myocardial Involvement of Cardiac Sarcoidosis as Assessed by ^{18}F -Fluorodeoxyglucose Positron Emission Tomography?. Circulation: Cardiovascular Imaging, 2013, 6, 617-626.	2.6	83
153	Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ^{18}F -FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model. Journal of Nuclear Medicine, 2013, 54, 1637-1644.	5.0	35
154	Loss of Cellular Inhibitor of Apoptosis Protein 2 Reduces Atherosclerosis in Atherogenic apoE $^{-/-}$ C57BL/6 Mice on High-Fat Diet. Journal of the American Heart Association, 2013, 2, e000259.	3.7	6
155	Current and Future Clinical Applications of Cardiac Positron Emission Tomography. Circulation Journal, 2013, 77, 836-848.	1.6	25
156	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure – OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). Trials, 2013, 14, 332.	1.6	5
157	Imaging-Guided Selection of Patients With Ischemic Heart Failure for High-Risk Revascularization Improves Identification of Those With the Highest Clinical Benefit. Circulation: Cardiovascular Imaging, 2012, 5, 262-270.	2.6	31
158	Rates of downstream invasive coronary angiography and revascularization: computed tomographic coronary angiography vs. Tc-99m single photon emission computed tomography. European Heart Journal, 2012, 33, 776-782.	2.2	17
159	The Use of ^{18}F -FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience. Journal of Nuclear Medicine, 2012, 53, 241-248.	5.0	438
160	Imaging the failing right ventricle. Current Opinion in Cardiology, 2012, 27, 148-153.	1.8	15
161	Nuclear perfusion imaging for functional evaluation of patients with known or suspected coronary artery disease: the future is now. Future Cardiology, 2012, 8, 603-622.	1.2	5
162	Measuring coronary artery calcification using positron emission tomography-computed tomography attenuation correction images. European Heart Journal Cardiovascular Imaging, 2012, 13, 786-792.	1.2	43

#	ARTICLE	IF	CITATIONS
163	Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy. <i>Europace</i> , 2012, 14, 690-695.	1.7	33
164	¹⁸ F-FDG Cell Labeling May Underestimate Transplanted Cell Homing: More Accurate, Efficient, and Stable Cell Labeling with Hexadecyl-4-[¹⁸ F]Fluorobenzoate for in Vivo Tracking of Transplanted Human Progenitor Cells by Positron Emission Tomography. <i>Cell Transplantation</i> , 2012, 21, 1821-1835.	2.5	29
165	Uniformity and repeatability of normal resting myocardial blood flow in rats using [¹³ N]-ammonia and small animal PET. <i>Nuclear Medicine Communications</i> , 2012, 33, 917-925.	1.1	11
166	Does Rubidium-82 PET Have Superior Accuracy to SPECT Perfusion Imaging for the Diagnosis of Obstructive Coronary Disease?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1828-1837.	2.8	297
167	Does FDG PET-Assisted Management of Patients With Left Ventricular Dysfunction Improve Quality of Life? A Substudy of the PARR-2 Trial. <i>Canadian Journal of Cardiology</i> , 2012, 28, 54-61.	1.7	17
168	135 The Association Between Patterns of Myocardial Involvement and Clinical Presentation in Patients With Cardiac Sarcoidosis As Assessed By FDG-PET. <i>Canadian Journal of Cardiology</i> , 2012, 28, S140-S141.	1.7	1
169	170 Quantitative Scar Imaging Using Multislice Computed Tomography Versus Metabolic Imaging By F-18 FDG Positron Emission Tomography: A Proof Of Concept Study. <i>Canadian Journal of Cardiology</i> , 2012, 28, S154-S155.	1.7	0
170	194 Downstream Utilization of Cardiac Investigations in Coronary Artery Bypass Patients: A Comparison of Anatomical Versus Functional Index Imaging With CT Coronary Angiography or Cardiac SPECT. <i>Canadian Journal of Cardiology</i> , 2012, 28, S164-S165.	1.7	1
171	236 Decreased \hat{I}^2 -Adrenoceptor Binding in High-Fat Diet Low-Dose Streptozotocin Rats is Normalized With Similar Efficacy by 2 or 7 Weeks of Insulin-Induced Euglycemia. <i>Canadian Journal of Cardiology</i> , 2012, 28, S177-S178.	1.7	0
172	721 Assessment of Aortic Plaque Inflammation and Its Relationship With Aortic Dilatation by FDG PET/CT Hybrid Imaging. <i>Canadian Journal of Cardiology</i> , 2012, 28, S376-S377.	1.7	0
173	Patient Management After Noninvasive Cardiac Imaging. <i>Journal of the American College of Cardiology</i> , 2012, 59, 462-474.	2.8	188
174	Short-term repeatability of resting myocardial blood flow measurements using rubidium-82 PET imaging. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 997-1006.	2.1	68
175	Accuracy of low-dose rubidium-82 myocardial perfusion imaging for detection of coronary artery disease using 3D PET and normal database interpretation. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 1135-1145.	2.1	40
176	Imaging atherosclerosis with hybrid [¹⁸ F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: What Leonardo da Vinci could not see. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 1211-1225.	2.1	55
177	A fast, simple, and reproducible automated synthesis of [¹⁸ F]FPyKYNE (RGDyK) for \hat{I}^2 receptor positron emission tomography imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 57-60.	1.0	18
178	Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease?. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 670-680.	2.1	252
179	Usefulness of Beta-Blocker Therapy and Outcomes in Patients With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 109, 1504-1509.	1.6	70
180	Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 73-83.	2.1	16

#	ARTICLE	IF	CITATIONS
181	Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 314-34.	1.0	16
182	Impaired Myocardial Flow Reserve on Rubidium-82 Positron Emission Tomography Imaging Predicts Adverse Outcomes in Patients Assessed for Myocardial Ischemia. <i>Journal of the American College of Cardiology</i> , 2011, 58, 740-748.	2.8	498
183	178 Abnormal Neonate Cardiomyocyte Metabolism is Associated with Alterations in Adult Cardiac Metabolism in a Mouse Model of the Arg302Gln-prkag2 Cardiac Syndrome. <i>Canadian Journal of Cardiology</i> , 2011, 27, S123-S124.	1.7	0
184	487 The use of 18F-FDG to detect changes in atherosclerotic lesions in atherogenic apoE $\hat{\alpha}^{\wedge}/\hat{\alpha}^{\wedge}$ mice. <i>Canadian Journal of Cardiology</i> , 2011, 27, S238-S239.	1.7	0
185	516 Cardiac fdg pet results impact decisions and identify patients likely to benefit from revascularization in a multi-center provincial registry (CADRE). <i>Canadian Journal of Cardiology</i> , 2011, 27, S249-S250.	1.7	3
186	577 The role of fluorodeoxyglucose positron emission tomography guided management in improving quality of life amongst patients with ischemic left ventricular dysfunction. <i>Canadian Journal of Cardiology</i> , 2011, 27, S269-S270.	1.7	0
187	578 Pet imaging standards and quality assurance for the rubidium ARMI (alternative) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 507 27, S270.	1.7	0
188	647 Imaging of atherosclerotic vascular lesions in ApoE-/- mice Using [18F]-PyKYNE-c(RGDyK) and PET. <i>Canadian Journal of Cardiology</i> , 2011, 27, S298.	1.7	0
189	671 Increased Cardiac AT1R in the post ischemic myocardium in a transient left anterior descending artery ligation/reperfusion rat model. <i>Canadian Journal of Cardiology</i> , 2011, 27, S307-S308.	1.7	0
190	705 Development of reporter gene PET imaging techniques for long-term assessment of transplanted human circulating progenitor cells. <i>Canadian Journal of Cardiology</i> , 2011, 27, S321-S322.	1.7	0
191	Right Ventricle Glucose Metabolism and Pressure Overload in Patients with Pulmonary Arterial Hypertension. <i>Journal of Cardiac Failure</i> , 2011, 17, S16.	1.7	0
192	Reduced CGP12177 binding to cardiac $\hat{1}^2$ -adrenoceptors in hyperglycemic high-fat-diet-fed, streptozotocin-induced diabetic rats. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1059-1066.	0.6	19
193	PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram. <i>Current Radiopharmaceuticals</i> , 2011, 4, 44-58.	0.8	11
194	Recent advances in cardiac imaging for patients with heart failure. <i>Current Opinion in Cardiology</i> , 2011, 26, 132-143.	1.8	28
195	Hexokinase II acts through UCP3 to suppress mitochondrial reactive oxygen species production and maintain aerobic respiration. <i>Biochemical Journal</i> , 2011, 437, 301-311.	3.7	32
196	Altered myocardial glucose utilization and the reverse mismatch pattern on rubidium-82 perfusion/F-18-FDG PET during the sub-acute phase following reperfusion of acute anterior myocardial infarction. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 657-667.	2.1	16
197	Incremental prognostic value of coronary flow reserve assessed with single-photon emission computed tomography. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 541-543.	2.1	2
198	Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. <i>Cardiovascular Diabetology</i> , 2011, 10, 75.	6.8	59

#	ARTICLE	IF	CITATIONS
199	[¹¹ C]Methyl ¹¹ Losartan as a potential ligand for PET imaging angiotensin II AT ₁ receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 754-757.	1.0	9
200	PET of (<i>R</i>)- ¹¹ C-Rolipram Binding to Phosphodiesterase-4 Is Reproducible and Sensitive to Increased Norepinephrine in the Rat Heart. Journal of Nuclear Medicine, 2011, 52, 263-269.	5.0	16
201	Influence of Noninvasive Cardiovascular Imaging in Primary Prevention. Archives of Internal Medicine, 2011, 171, 977-82.	3.8	22
202	Cardiovascular Nuclear Imaging: Balancing Proven Clinical Value and Potential Radiation Risk. Journal of Nuclear Medicine, 2011, 52, 1162-1164.	5.0	20
203	Kinetic model-based factor analysis of dynamic sequences for ⁸² Rubidium cardiac positron emission tomography. Medical Physics, 2010, 37, 3995-4010.	3.0	18
204	Naturally occurring R225W mutation of the gene encoding AMP-activated protein kinase (AMPK) ³ results in increased oxidative capacity and glucose uptake in human primary myotubes. Diabetologia, 2010, 53, 1986-1997.	6.3	22
205	Right and left ventricular uptake with Rb-82 PET myocardial perfusion imaging: Markers of left main or 3 vessel disease. Journal of Nuclear Cardiology, 2010, 17, 52-60.	2.1	14
206	Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. Journal of Nuclear Cardiology, 2010, 17, 254-263.	2.1	37
207	Intra- and inter-operator repeatability of myocardial blood flow and myocardial flow reserve measurements using rubidium-82 pet and a highly automated analysis program. Journal of Nuclear Cardiology, 2010, 17, 600-616.	2.1	126
208	Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Pro. Journal of Nuclear Cardiology, 2010, 17, 683-695.	2.1	23
209	Quantification of myocardial blood flow and flow reserve: Technical aspects. Journal of Nuclear Cardiology, 2010, 17, 555-570.	2.1	149
210	The clinical utility of assessing myocardial blood flow using positron emission tomography. Journal of Nuclear Cardiology, 2010, 17, 571-581.	2.1	35
211	Usefulness of Computed Tomographic Coronary Angiography in Patients With Acute Chest Pain With and Without High-Risk Features. American Journal of Cardiology, 2010, 106, 463-469.	1.6	20
212	Radiosynthesis of N-[¹¹ C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs). Applied Radiation and Isotopes, 2010, 68, 325-328.	1.5	13
213	Effects of Mitral Valve Surgery on Myocardial Energetics in Patients With Severe Mitral Regurgitation. Circulation: Cardiovascular Imaging, 2010, 3, 308-313.	2.6	19
214	Single-Phase CT Aligned to Gated PET for Respiratory Motion Correction in Cardiac PET/CT. Journal of Nuclear Medicine, 2010, 51, 1182-1190.	5.0	35
215	¹⁸ F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to ¹⁸ F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial. Journal of Nuclear Medicine, 2010, 51, 567-574.	5.0	135
216	Assessment of myocardial ischaemia and viability: role of positron emission tomography. European Heart Journal, 2010, 31, 2984-2995.	2.2	117

#	ARTICLE	IF	CITATIONS
217	3D versus 2D dynamic ⁸² Rb myocardial blood flow imaging in a canine model of stunned and infarcted myocardium. <i>Nuclear Medicine Communications</i> , 2010, 31, 75-81.	1.1	7
218	Quantification of regional myocardial blood flow in a canine model of stunned and infarcted myocardium: comparison of rubidium-82 positron emission tomography with microspheres. <i>Nuclear Medicine Communications</i> , 2010, 31, 67-74.	1.1	11
219	Validation of Conventional and Simplified Methods to Calculate Projected Valve Area at Normal Flow Rate in Patients With Low Flow, Low Gradient Aortic Stenosis: The Multicenter TOPAS (True or Pseudo) Tj ETQq1 1 2 3 7 8 4 3 1 4 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234	2.7	8431
220	Prognostic Value of 64-Slice Cardiac Computed Tomography. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1017-1028.	2.8	256
221	Screening patients for primary prophylaxis implantable cardioverter defibrillators: Insights into current practices. <i>Canadian Journal of Cardiology</i> , 2010, 26, e125-e127.	1.7	0
222	Diagnosis and Prognosis in Cardiac Disease Using Cardiac PET Perfusion Imaging. , 2010, , 309-331.		4
223	Diagnostic Accuracy and Impact of Computed Tomographic Coronary Angiography on Utilization of Invasive Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2009, 2, 16-23.	2.6	136
224	In Vivo Assessment of Myocardial Glucose Uptake by Positron Emission Tomography in Adults With the <i>PRKAG2</i> Cardiac Syndrome. <i>Circulation: Cardiovascular Imaging</i> , 2009, 2, 485-491.	2.6	15
225	Novel O-[¹¹ C]methylated derivatives of candesartan as angiotensin II AT1 receptor imaging ligands: Radiosynthesis and ex vivo evaluation in rats. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7971-7977.	3.0	21
226	Quantification of Myocardial Flow Reserve Using Positron Emission Imaging. <i>Journal of the American College of Cardiology</i> , 2009, 54, 157-159.	2.8	22
227	Potential Clinical and Economic Consequences of Noncardiac Incidental Findings on Cardiac Computed Tomography. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1533-1541.	2.8	145
228	Increasing Benefit From Revascularization Is Associated With Increasing Amounts of Myocardial Hibernation. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 1060-1068.	5.3	159
229	Reduced in vivo phosphodiesterase-4 response to acute noradrenaline challenge in diet-induced obese rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2009, 87, 196-202.	1.4	7
230	Prognostic value of treadmill exercise and dobutamine stress positron emission tomography. <i>Canadian Journal of Cardiology</i> , 2009, 25, e220-e224.	1.7	13
231	Cardiac Positron Emission Tomography: Current Clinical Practice. <i>Cardiology Clinics</i> , 2009, 27, 237-255.	2.2	21
232	Effect of lateral wall scar on reverse remodeling with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2009, 6, 1721-1726.	0.7	32
233	Cardiovascular Drug Development Using Radiopharmaceuticals. <i>Current Pharmaceutical Design</i> , 2009, 15, 935-942.	1.9	2
234	Use of a column-switching high-performance liquid chromatography method to assess the presence of specific binding of (R)- and (S)-[¹¹ C]rolipram and their labeled metabolites to the phosphodiesterase-4 enzyme in rat plasma and tissues. <i>Nuclear Medicine and Biology</i> , 2008, 35, 515-521.	0.6	19

#	ARTICLE	IF	CITATIONS
235	Acute and chronic effects of continuous positive airway pressure therapy on left ventricular systolic and diastolic function in patients with obstructive sleep apnea and congestive heart failure. <i>Canadian Journal of Cardiology</i> , 2008, 24, 697-704.	1.7	43
236	Predictors of Outcomes in Low-Flow, Low-Gradient Aortic Stenosis. <i>Circulation</i> , 2008, 118, S234-42.	1.6	208
237	Is ventilatory efficiency (VE/VCO_2 slope) associated with right ventricular oxidative metabolism in patients with congestive heart failure?. <i>European Journal of Heart Failure</i> , 2008, 10, 1117-1122.	7.1	28
238	Collagen-Based Matrices Improve the Delivery of Transplanted Circulating Progenitor Cells. <i>Circulation: Cardiovascular Imaging</i> , 2008, 1, 197-204.	2.6	51
239	3D list-mode cardiac PET for simultaneous quantification of myocardial blood flow and ventricular function. , 2008, , .		6
240	Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography. <i>Current Pharmaceutical Design</i> , 2008, 14, 3835-3853.	1.9	44
241	Sleep apnea in chronic heart failure. <i>Current Opinion in Cardiology</i> , 2008, 23, 121-126.	1.8	10
242	B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis. <i>Circulation</i> , 2007, 115, 2848-2855.	1.6	133
243	Presence of Specific ¹¹ C-meta-Hydroxyephedrine Retention in Heart, Lung, Pancreas, and Brown Adipose Tissue. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1733-1740.	5.0	41
244	A minimal factor overlap method for resolving ambiguity in factor analysis of dynamic cardiac PET. , 2007, , .		2
245	Positron molecular imaging, an in vivo glimpse of the genome. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 43, 11-14.	1.9	2
246	In vivo selective binding of (R)-[¹¹ C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues. <i>Nuclear Medicine and Biology</i> , 2007, 34, 71-77.	0.6	21
247	Angina pectoris: Has the cornerstone of symptomatic coronary artery disease been moved?. <i>Canadian Journal of Cardiology</i> , 2007, 23, 648-650.	1.7	1
248	Comparison of computed tomographic angiography versus rubidium-82 positron emission tomography for the detection of patients with anatomical coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2007, 23, 801-807.	1.7	15
249	CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease – executive summary. <i>Canadian Journal of Cardiology</i> , 2007, 23, 107-119.	1.7	93
250	The Effects of Continuous Positive Airway Pressure on Myocardial Energetics in Patients With Heart Failure and Obstructive Sleep Apnea. <i>Journal of the American College of Cardiology</i> , 2007, 49, 450-458.	2.8	66
251	F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2002-2012.	2.8	403
252	Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 380-397.	2.1	86

#	ARTICLE	IF	CITATIONS
253	Treating the right patient at the right time: Access to specialist consultation and noninvasive testing. Canadian Journal of Cardiology, 2006, 22, 819-824.	1.7	25
254	Treating the right patient at the right time: Access to cardiovascular nuclear imaging. Canadian Journal of Cardiology, 2006, 22, 827-833.	1.7	6
255	Native anomalous left coronary artery from the pulmonary artery in an adult: Evidence of impaired coronary flow reserve by rubidium-82 positron emission tomography quantification. Canadian Journal of Cardiology, 2006, 22, 1069-1070.	1.7	0
256	Treadmill Exercise Produces Larger Perfusion Defects Than Dipyridamole Stress N-13 Ammonia Positron Emission Tomography. Journal of the American College of Cardiology, 2006, 47, 411-416.	2.8	62
257	What is the Prognostic Value of Myocardial Perfusion Imaging Using Rubidium-82 Positron Emission Tomography?. Journal of the American College of Cardiology, 2006, 48, 1029-1039.	2.8	333
258	Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart. Life Sciences, 2006, 79, 356-364.	4.3	23
259	Kinetics of (R)-[11C] rolipram and (S)-[11C] rolipram In the Dog Heart: Investigation of Four Compartment Models. , 2006, , .		0
260	Projected Valve Area at Normal Flow Rate Improves the Assessment of Stenosis Severity in Patients With Low-Flow, Low-Gradient Aortic Stenosis. Circulation, 2006, 113, 711-721.	1.6	237
261	Response to Letter Regarding Article, "Projected Valve Area at Normal Flow Rate Improves the Assessment of Stenosis Severity in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The Multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) Study". Circulation, 2006, 114, .	1.6	0
262	Application of Cardiac Molecular Imaging Using Positron Emission Tomography in Evaluation of Drug and Therapeutics for Cardiovascular Disorders. Current Pharmaceutical Design, 2005, 11, 903-932.	1.9	46
263	Fluorine-18 Labeled Deoxyglucose Positron Emission Tomography in the Diagnosis and Management of Aortitis With Pulmonary Artery Involvement. Circulation, 2005, 111, e375-6.	1.6	6
264	Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography. Journal of the American College of Cardiology, 2005, 45, 1227-1234.	2.8	50
265	Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). Journal of the American College of Cardiology, 2005, 46, 417-424.	2.8	221
266	Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. Journal of Nuclear Medicine, 2005, 46, 1095-101.	5.0	49
267	Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease*1. Journal of Nuclear Cardiology, 2004, 11, 440-449.	2.1	246
268	A infusion system for quantitative perfusion imaging with 3D PET. Applied Radiation and Isotopes, 2004, 60, 921-927.	1.5	13
269	Phantom Studies Investigating Extravascular Density Imaging for Partial Volume Correction of 3-D PET<tex>\$^{18}\$</tex>FDG Studies. IEEE Transactions on Nuclear Science, 2004, 51, 68-71.	2.0	7
270	Hematopoietic stem cell (HSC) redistribution for cardiac repair following acute myocardial infarction (AMI). Biology of Blood and Marrow Transplantation, 2004, 10, 81.	2.0	0

#	ARTICLE	IF	CITATIONS
271	Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Contemporary Clinical Trials, 2003, 24, 776-794.	1.9	22
272	Pet myocardial perfusion and glucose metabolism imaging: part 2â€”guidelines for interpretation and reporting. Journal of Nuclear Cardiology, 2003, 10, 557-571.	2.1	71
273	Gated fluorine 18 fluorodeoxyglucose positron emission tomography: determination of global and regional left ventricular function and myocardial tissue characterization. Journal of Nuclear Cardiology, 2003, 10, 297-303.	2.1	22
274	Hospitalization Costs of Primary Stenting Versus Thrombolysis in Acute Myocardial Infarction. Circulation, 2003, 108, 2624-2630.	1.6	42
275	Effect of Cardiac Resynchronization on Myocardial Efficiency and Regional Oxidative Metabolism. Circulation, 2003, 107, 28-31.	1.6	192
276	Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. Journal of the American College of Cardiology, 2002, 40, 1735-1743.	2.8	174
277	Stenting versus thrombolysis in acute myocardial infarction trial (STAT). Journal of the American College of Cardiology, 2001, 37, 985-991.	2.8	98
278	Patient management guided by viability imaging. Journal of the American College of Cardiology, 2001, 38, 1271-1272.	2.8	5
279	Evaluation of myocardial perfusion using rubidium-82 positron emission tomography after myocardial infarction in patients receiving primary stent implantation or thrombolytic therapy. American Journal of Cardiology, 2001, 88, 886-889.	1.6	12
280	Stress perfusion/metabolism imaging: A pilot study for a potential new approach to the diagnosis of coronary disease in women. Journal of Nuclear Cardiology, 2000, 7, 205-212.	2.1	26
281	The Effects of β_1 -Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular Dysfunction. Circulation, 2000, 102, 2070-2075.	1.6	161
282	Establishing an approach for patients with recent coronary occlusion: Identification of viable myocardium. Journal of Nuclear Cardiology, 1999, 6, 298-305.	2.1	8
283	Manufacture of strontium-82/rubidium-82 generators and quality control of rubidium-82 chloride for myocardial perfusion imaging in patients using positron emission tomography. Applied Radiation and Isotopes, 1999, 50, 1015-1023.	1.5	36
284	Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction. American Heart Journal, 1999, 137, 863-869.	2.7	27
285	Assessment of Diagnostic Performance of Quantitative Flow Measurements in Normal Subjects and Patients With Angiographically Documented Coronary Artery Disease by Means of Nitrogen-13 Ammonia and Positron Emission Tomography. Journal of the American College of Cardiology, 1998, 31, 534-540.	2.8	136
286	Late clinical and angiographic follow-up after stenting in evolving and recent myocardial infarction. American Heart Journal, 1998, 135, 714-718.	2.7	2
287	Can Nitrogen-13 Ammonia Kinetic Modeling Define Myocardial Viability Independent of Fluorine-18 Fluorodeoxyglucose?. Journal of the American College of Cardiology, 1997, 29, 537-543.	2.8	27
288	Differentiation of myocardial ischemia and necrosis by technetium 99m glucaric acid kinetics*1. Journal of Nuclear Cardiology, 1997, 4, 274-282.	2.1	9

#	ARTICLE	IF	CITATIONS
289	Evaluation of simulation-based scatter correction for 3-D PET cardiac imaging. IEEE Transactions on Nuclear Science, 1997, 44, 90-97.	2.0	171
290	F-18-Fluorodeoxyglucose PET Imaging Alters Clinical Decision Making in Patients With Impaired Ventricular Function. American Journal of Cardiology, 1997, 79, 1092-1095.	1.6	42
291	Comparison of Tc-99m Sestamibi Perfusion Imaging and Echocardiography Using an Arbutamine Infusion for the Detection of Coronary Artery Disease. American Journal of Cardiology, 1997, 79, 1518-1521.	1.6	1
292	Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia labeled positron emission tomography*. Journal of Nuclear Cardiology, 1995, 2, 413-422.	2.1	66
293	Heterogeneity of ventricular function and myocardial oxidative metabolism in nonischemic dilated cardiomyopathy. Journal of the American College of Cardiology, 1995, 25, 1258-1262.	2.8	43
294	Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Journal of the American College of Cardiology, 1995, 26, 1465-1475.	2.8	143
295	Redistribution of Myocardial Blood Flow With Topical Nitroglycerin in Patients With Coronary Artery Disease. Circulation, 1995, 91, 1381-1388.	1.6	43
296	The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. Journal of Nuclear Cardiology, 1994, 1, 3-16.	2.1	45
297	Heterogeneity of regional nitrogen 13-labeled ammonia tracer distribution in the normal human heart: Comparison with rubidium 82 and copper 62-labeled PTSM. Journal of Nuclear Cardiology, 1994, 1, 225-235.	2.1	40
298	Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. Journal of the American College of Cardiology, 1994, 23, 92-98.	2.8	132
299	Alterations in Fatty Acid Metabolism in Adriamycin Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1994, 26, 109-119.	1.9	17
300	Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 1993, 22, 1389-1398.	2.8	117
301	Noninvasive quantification of myocardial perfusion using positron emission tomography. Coronary Artery Disease, 1992, 3, 281-290.	0.7	1
302	The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow. Journal of the American College of Cardiology, 1992, 20, 712-719.	2.8	49
303	Comparison of technetium-99m sestamibi and thallium-201 retention characteristics in canine myocardium. Journal of the American College of Cardiology, 1992, 20, 1277-1283.	2.8	42
304	Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability?. Circulation, 1990, 82, 1802-1814.	1.6	177